Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2013

01-09-2013 | Thoracic Oncology

Nodal Skip Metastasis is not a Predictor of Survival in Thoracic Esophageal Squamous Cell Carcinoma

Authors: Zhengfei Zhu, MD, Weiwei Yu, MD, Hecheng Li, MD, Kuaile Zhao, MD, Weixin Zhao, MD, Yawei Zhang, MD, Menghong Sun, MD, Qiao Wei, MD, Haiquan Chen, MD, Jiaqing Xiang, MD, Xiaolong Fu, MD

Published in: Annals of Surgical Oncology | Issue 9/2013

Login to get access

Abstract

Background

The presence of nodal skip metastasis (NSM) has been found to be of clinical importance in non-small cell lung cancer, but the study of this phenomenon in esophageal carcinoma is relatively rare. The purpose of this study was to identify risk factors influencing NSM and to assess its prognostic value in thoracic esophageal squamous cell carcinoma (ESCC).

Methods

A total of 207 patients with thoracic ESCC who underwent three-field lymphadenectomy and who had lymph node metastasis were reviewed. Associations of NSM occurrence with the clinicopathological characteristics of patients and primary tumors were evaluated using logistic regression analysis. The influence of NSM on the overall survival (OS) was assessed by log-rank tests and Cox regression analysis.

Results

NSM were present in 58 (26 %) patients. No factor was significantly associated with the incidence of NSM except for the location of primary tumor. There were no NSMs in the 29 patients from our study with upper thoracic ESCC, and the rates of tumors occurrence in the middle and lower third of the esophagus were 38.9 and 14.9 %, respectively. The median OS was 30 months, and no significant difference in OS was found between the patients with or without NSM (p = 0.767). Only N status was found to be the independent risk factor for OS by Cox multivariate analysis.

Conclusions

NSM is common in thoracic ESCC, especially in patients with tumors located in the middle and lower third of the esophagus. However, the presence of NSM did not predict prognosis.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American joint committee on cancer (AJCC) cancer staging manual, 7th edn. Chicago: Springer; 2010:67–72.
4.
Tachibana M, Kinugasa S, Hirahara N, Yoshimura H. Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg. 2008;34:427–31.PubMedCrossRef
5.
Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec Barthes F, Dujon A, Danel C. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–33.PubMedCrossRef
6.
Nakagiri T, Sawabata N, Funaki S, Inoue M, Kadota Y, Shintani Y, Okumura M. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2011;12:733–8.PubMedCrossRef
7.
Lim YC, Koo BS. Predictive factors of skip metastases to lateral neck compartment leaping central neck compartment in papillary thyroid carcinoma. Oral Oncol. 2012;4:262–265.CrossRef
8.
Lee SE, Lee JH, Ryu KW, et al. Sentinel node mapping and skip metastases in patients with early gastric cancer. Ann Surg Oncol. 2009;16:603–608.PubMedCrossRef
9.
Keskek M, Balas S, Gokoz A, Sayek I. Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today. 2006;36:1047–1052.PubMedCrossRef
10.
Li H, Zhang Y, Cai H, Xiang J. Pattern of lymph node metastases in patients with squamous cell carcinoma of the thoracic esophagus who underwent three-field lymphadenectomy. Eur Surg Res. 2007;39:1–6.PubMedCrossRef
11.
Li H, Yang S, Zhang Y, Xiang J, Chen H. Thoracic recurrent laryngeal lymph node metastases predict cervical node metastases and benefit from three-field dissection in selected patients with thoracic esophageal squamous cell carcinoma. J Surg Oncol. 2012;105:548–552.PubMedCrossRef
12.
Japanese Society for Esophageal Diseases: Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. Jpn J Surg. 1976;6:69–78.PubMedCrossRef
13.
Prenzel KL, Bollschweiler E, Schröder W, Mönig SP, Drebber U, Vallboehmer D, Hölscher AH. Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg. 2010;90:1662–1667.PubMedCrossRef
14.
Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001;19:1970–1975.PubMed
15.
Xu QR, Zhuge XP, Zhang HL, Ping YM, Chen LQ. The N-classification for esophageal cancer staging: should it be based on number, distance, or extent of the lymph node metastasis? World J Surg. 2011;35:1303–1310.PubMedCrossRef
16.
Skandalakis JE, Ellis H. Embryologic and anatomic basis of esophageal surgery. Surg Clin North Am. 2000;80:85–155.PubMedCrossRef
17.
Takeuchi H, Fujii H, Ando N, et al. Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg. 2009;249:757–763.PubMedCrossRef
18.
Kim HK, Kim S, Park JJ, Jeong JM, Mok YJ, Choi YH. Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer. Ann Thorac Surg. 2011;91:1517–1522.PubMedCrossRef
19.
Chen J, Liu S, Pan J, et al. The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2009;36:480–486.PubMedCrossRef
20.
Groth SS, Virnig BA, Whitson BA, DeFor TE, Li ZZ, Tuttle TM, Maddaus MA. Determination of the minimum number of LNs to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg. 2010;139:612–620.PubMedCrossRef
21.
22.
Gusterson B, Ott R. Occult axillary lymph-node micrometastases in breast cancer. Lancet. 1990;336:434–435.CrossRef
23.
Yekebas EF, Schurr PG, Kaifi JT, et al. Effectiveness of radical en bloc esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol. 2006;93:541–549.PubMedCrossRef
24.
Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in LNs of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188–1194.PubMedCrossRef
Metadata
Title
Nodal Skip Metastasis is not a Predictor of Survival in Thoracic Esophageal Squamous Cell Carcinoma
Authors
Zhengfei Zhu, MD
Weiwei Yu, MD
Hecheng Li, MD
Kuaile Zhao, MD
Weixin Zhao, MD
Yawei Zhang, MD
Menghong Sun, MD
Qiao Wei, MD
Haiquan Chen, MD
Jiaqing Xiang, MD
Xiaolong Fu, MD
Publication date
01-09-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2987-5

Other articles of this Issue 9/2013

Annals of Surgical Oncology 9/2013 Go to the issue

Thoracic Oncology

EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases

Pancreatic Tumors

Preoperative Classification of Pancreatic Cystic Neoplasms: The Clinical Significance of Diagnostic Inaccuracy

Gastrointestinal Oncology

D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging

Pancreatic Tumors

Posterior Approach for Laparoscopic Pancreaticoduodenectomy to Prevent Replaced Hepatic Artery Injury

Healthcare Policy and Outcomes

Prognosis in Women with Breast Cancer and Private Extra Insurance Coverage

Head and Neck Oncology

Thyroid Nodules with Bethesda System III Cytology: Can Ultrasonography Guide the Next Step?